XML 29 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid In Capital
Retained Earnings
Unearned ESOP Shares
Accumulated Other Comprehensive Loss
Balance at beginning of period (in shares) at Dec. 31, 2022   15,673,595        
Balance at beginning of period at Dec. 31, 2022 $ 410,155 $ 157 $ 128,486 $ 290,271 $ (5,026) $ (3,733)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 21,747     21,747    
Cash dividends declared on common stock (3,367)     (3,367)    
Retired stock (in shares)   (9,066)        
Retired stock (249)   (249)      
Granted restricted stock (in shares)   53,339        
Stock issued for Quantum acquisition (in shares)   1,374,646        
Stock issued for Quantum acquisition $ 37,734 $ 14 37,720      
Forfeited restricted stock (in shares)   (3,890)        
Exercised stock options (in shares) 278,049 278,049        
Exercised stock options $ 4,075 $ 3 4,072      
Share-based compensation expense 823   823      
ESOP compensation expense 635   370   265  
Other comprehensive income (loss) (367)         (367)
Balance at end of period (in shares) at Jun. 30, 2023   17,366,673        
Balance at end of period at Jun. 30, 2023 471,186 $ 174 171,222 308,651 (4,761) (4,100)
Balance at beginning of period (in shares) at Mar. 31, 2023   17,370,063        
Balance at beginning of period at Mar. 31, 2023 458,242 $ 174 170,670 295,325 (4,893) (3,034)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 15,013     15,013    
Cash dividends declared on common stock (1,687)     (1,687)    
Forfeited restricted stock (in shares)   (3,890)        
Exercised stock options (in shares)   500        
Exercised stock options 9   9      
Share-based compensation expense 389   389      
ESOP compensation expense 286   154   132  
Other comprehensive income (loss) (1,066)         (1,066)
Balance at end of period (in shares) at Jun. 30, 2023   17,366,673        
Balance at end of period at Jun. 30, 2023 $ 471,186 $ 174 171,222 308,651 (4,761) (4,100)
Balance at beginning of period (in shares) at Dec. 31, 2023 17,387,069 17,387,069        
Balance at beginning of period at Dec. 31, 2023 $ 499,893 $ 174 172,366 333,401 (4,497) (1,551)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 27,485     27,485    
Cash dividends declared on common stock (3,739)     (3,739)    
Common stock repurchased (in shares)   (23,483)        
Common stock repurchased (645)   (645)      
Retired stock (in shares)   (8,762)        
Retired stock $ (233)   (233)      
Granted restricted stock (in shares)   72,502        
Exercised stock options (in shares) 10,000 10,000        
Exercised stock options $ 159 $ 1 158      
Share-based compensation expense 822   822      
ESOP compensation expense 704   439   265  
Other comprehensive income (loss) $ (818)         (818)
Balance at end of period (in shares) at Jun. 30, 2024 17,437,326 17,437,326        
Balance at end of period at Jun. 30, 2024 $ 523,628 $ 175 172,907 357,147 (4,232) (2,369)
Balance at beginning of period (in shares) at Mar. 31, 2024   17,444,787        
Balance at beginning of period at Mar. 31, 2024 513,173 $ 175 172,919 346,598 (4,364) (2,155)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 12,418     12,418    
Cash dividends declared on common stock (1,869)     (1,869)    
Common stock repurchased (in shares)   (23,483)        
Common stock repurchased (645)   (645)      
Granted restricted stock (in shares)   16,022        
Share-based compensation expense 409   409      
ESOP compensation expense 356   224   132  
Other comprehensive income (loss) $ (214)         (214)
Balance at end of period (in shares) at Jun. 30, 2024 17,437,326 17,437,326        
Balance at end of period at Jun. 30, 2024 $ 523,628 $ 175 $ 172,907 $ 357,147 $ (4,232) $ (2,369)